Intensive CTD immunotherapy was confirmed to result in an earlier NT-proBNP remission in our cohort, which provided evidence for establishing strategies for using CTD immunotherapy in CTD-PAH. The gene discussed is NPPB; the disease is pulmonary arterial hypertension.